





Sulfadoxine + pyrimethamine

Essential medicine status 

Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.3. Antimalarial medicines](#) > [6.5.3.1. Antimalarial medicines](#) > Medicines for curative treatment

EMLc

ATC codes: [P01BD51](#)

Indication	Malaria due to Plasmodium vivax ICD11 code: 1F81
INN	Sulfadoxine + pyrimethamine
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Additional notes	Only in combination with artesunate 50 mg
Formulations	Oral > Solid: 500 mg + 25 mg tablet
EML status history	First added in 1979 (TRS 641) Changed in 1987 (TRS 770) Changed in 2003 (TRS 920) Changed in 2007 (TRS 946) Changed in 2007 (TRS 950)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents . 
Wikipedia	Sulfadoxine + pyrimethamine 
DrugBank	Sulfadoxine  , Pyrimethamine 

Summary of evidence and Expert Committee recommendations

Sulfadoxine + pyrimethamine tablets 500 mg + 25 mg was added to the EMLc for the curative treatment of malaria.

